Search clinical trials for: high risk melanoma

Total 34097 results

University of Utah

Not yet recruiting

Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma (NeoRelapse)

Melanoma

United States
University Health Network, Toronto

Recruiting

Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma (ClearMe)

Cutaneous Melanoma | Mucosal Melanoma | Melanoma Stage IV

Canada
European Organisation for Research and Treatment...
Northwell Health Cancer Institute

Not yet recruiting

Adjuvant Tebentafusp in High Risk Ocular Melanoma (ATOM)

Uveal Melanoma
The Netherlands Cancer Institute

Not yet recruiting

Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma (MARIANE)

Melanoma

Netherlands
James Isaacs, MD

Not yet recruiting

Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma

Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIID Melanoma

United States
OHSU Knight Cancer Institute
Oregon Health and Science University; Kuni Foundation

Recruiting

Atorvastatin for Preventing Disease Metastasis in Patients With Resected High-Risk Stage IIA Melanoma

Clinical Stage IIA Cutaneous Melanoma AJCC v8

United States
Merck Sharp & Dohme LLC
ModernaTX, Inc.

Recruiting

A Clinical Study of V940 Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)

Melanoma

Spain, Italy, Poland, Brazil, Australia, Chile, Canada, Portugal, Turkey, Germany, Greece, Israel, Sweden, New Zealand, United States, Belgium, France, Taiwan, United Kingdom, Switzerland, South Africa, Denmark, Argentina, Colombia
Regeneron Pharmaceuticals

Recruiting

A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

Melanoma

United States, Australia, Spain, United Kingdom, Canada, Brazil, Mexico, Germany, Ireland, South Africa, France, Israel, Georgia, Turkey, Italy, Poland, Chile, Argentina, Belgium, Czechia, Romania, Greece
Peking University Cancer Hospital & Institute

Recruiting

Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma

Melanoma | Temozolomide | Apatinib | Camrelizumab | Acral Melanoma | Neoadjuvant | Pathological Response

China
Melanoma Institute Australia
Bristol-Myers Squibb

Recruiting

A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma (Neo ReNi II)

Stage II Melanoma

Australia
Assistance Publique - Hôpitaux de Paris
Société de Dermatologie Française

Not yet recruiting

Characterization of NK Cells Under First Line Advanced Therapy Either as Curative Therapy for Metastatic Melanoma or as Adjuvant Therapy for High-risk of Recurrence (NAKIMEL)

Melanoma
Novartis Pharmaceuticals

Recruiting

Adjuvant Dabrafenib and Trametinib Treatment in Patients With Completely Resected High-risk Stage III Melanoma. (LEAD Melanoma)

Melanoma

Turkey
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI); Seagen Inc.

Recruiting

T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC... and other conditions

United States, Canada, Puerto Rico
National Cancer Institute (NCI)

Recruiting

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, Canada
Regeneron Pharmaceuticals
Sanofi

Recruiting

Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

Cutaneous Squamous Cell Carcinoma

United States, Australia, Spain, Germany, Belgium, Italy, France, Japan, United Kingdom, Brazil, Canada, Greece, Ireland, New Zealand, Poland, Russian Federation
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

Smoldering Plasma Cell Myeloma

United States
ModernaTX, Inc.
Merck Sharp & Dohme LLC

Recruiting

An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)

Melanoma

United States, Australia
University Health Network, Toronto

Recruiting

Liquid Biopsy Evaluation and Repository Development at Princess Margaret (LIBERATE)

Melanoma | Lymphoma | Kidney Cancer | Leukemia | Cancer | Breast Cancer | Head and Neck Cancer | Ovarian Cancer | Lynch Syndrome | Lung Cancer | Colon Cancer | Meningioma | BRCA1 Mutation | BRCA2 Mutation | Myeloma | Mutation | Uterine Cancer | Cowden Syndrome

Canada
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma

Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Pathologic Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIA Cutaneous Melanoma...

United States
Uppsala University

Recruiting

A Randomized Trial to Assess the Role of Imaging During Follow up After Radical Surgery of High Risk Melanoma (TRIM)

Malignant Melanoma

Sweden
Universitair Ziekenhuis Brussel

Recruiting

Whole-body DW-MRI and cfDNA Analysis for the Surveillance of Melanoma Patients at High Risk for Recurrence. (DW-MRi)

Melanoma

Belgium
National Cancer Institute (NCI)

Recruiting

Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma

Melanoma | Dysplastic Nevus Syndrome

United States
University Hospital, Essen

Active, not recruiting

Adjuvant Nivolumab Treatment in Stage II (IIA, IIB, IIC) High-risk Melanoma (NivoMela)

Malignant Melanoma Stage II

Germany
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)

Melanoma

Poland, Australia, Canada, United States, Argentina, Austria, Belgium, Brazil, Chile, China, Colombia, France, Germany, India, Ireland, Israel, Italy, Japan, Korea, Republic of, New Zealand, South Africa, Spain, Sweden, Switzerland, Turkey and more
National Cancer Institute (NCI)

Active, not recruiting

Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

Metastatic Cutaneous Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Recurrent Cutaneous Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Recurrent Mucosal Melanoma | Metastatic Mucosal Melanoma | Non-Cutaneous Melanoma | Metastatic Non-Cutaneous Melanoma | Recurrent Non-Cutaneous...

United States, Canada, Ireland
National Cancer Institute (NCI)

Active, not recruiting

Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery

Stage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Melanoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Melanoma of Unknown Primary | Stage IIIB Cutaneous Melanoma AJCC v7

United States, Canada
National Cancer Institute (NCI)

Active, not recruiting

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

Ganglioneuroblastoma | High Risk Neuroblastoma

United States, New Zealand, Australia
Memorial Sloan Kettering Cancer Center
Tel-Aviv Sourasky Medical Center; Sheba Medical Center; Princess Alexandra Hospital...

Active, not recruiting

Risk Stratification Among Individuals Who Have Many Moles on Their Skin

High-Risk Nevus Phenotype

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...
Pfizer

Active, not recruiting

Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma

Ciliary Body and Choroid Melanoma, Medium/Large Size | Ciliary Body and Choroid Melanoma, Small Size | Iris Melanoma | Stage IIIA Intraocular Melanoma | Stage IIIB Intraocular Melanoma | Stage IIIC Intraocular Melanoma | Stage I Intraocular Melanoma | Stage IIA Intraocular Melanoma | Stage IIB Intraocular... and other conditions

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma

Recurrent Melanoma | Stage IV Melanoma | Stage III Melanoma
NeoImmuneTech
Immune Oncology Network

Terminated

High-Risk Skin Cancers With Atezolizumab Plus NT-I7

Melanoma | Merkel Cell Carcinoma | Cutaneous Squamous Cell Carcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma

Clinical Stage III Cutaneous Melanoma AJCC v8 | Mucosal Melanoma | Acral Lentiginous Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8

United States
Merck Sharp & Dohme LLC

Active, not recruiting

Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)

Melanoma

Canada, United States, Australia, Belgium, Brazil, Chile, France, Germany, Israel, Italy, Japan, Poland, South Africa, Spain, Switzerland, United Kingdom
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery

Recurrent Colon Carcinoma | Recurrent Rectal Carcinoma | Rectal Adenocarcinoma | Colon Adenocarcinoma | ERBB2 Gene Amplification | Stage III Colon Cancer AJCC v7 | Stage III Rectal Cancer AJCC v7 | Stage IIIA Colon Cancer AJCC v7 | Stage IIIA Rectal Cancer AJCC v7 | Stage IIIB Colon Cancer AJCC v7 | Stage... and other conditions

United States, Puerto Rico
Fondazione Melanoma Onlus
Clinical Research Technology S.r.l.

Active, not recruiting

Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma (NEO-TIM)

Melanoma

Italy
University of Alabama at Birmingham

Withdrawn

A Biomarker Evaluation Trial of UAB30 in Renal Transplant Recipients at High Risk for Non-melanoma Skin Cancer

Non-melanoma Skin Cancer

United States
Columbia University
Pfizer

Completed

Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy

Uveal Melanoma

United States
Pierre Fabre Medicament
European Organisation for Research and Treatment of Cancer - EORTC

Active, not recruiting

Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. (COLUMBUS-AD)

Melanoma

Spain, Canada, Hungary, Italy, Belgium, Netherlands, Australia, Czechia, Greece, Brazil, Portugal, Serbia, Sweden, Norway, Germany, Argentina, Romania, Poland, United Kingdom, Austria, Switzerland, France, South Africa
Case Comprehensive Cancer Center

Active, not recruiting

Leveraging ctDNA Analysis to Improve Early Detection of Cancer Recurrence in the High-Risk Melanoma Setting

Stage III Melanoma | Stage IV Cutaneous Melanoma

United States
The Methodist Hospital Research Institute

Completed

Olive Oil for High Risk Breast Cancer Prevention in Women

Breast Cancer

United States
University of California, Davis
Amgen

Suspended

Neoadjuvant T-VEC in High Risk Early Melanoma

Melanoma

United States
St. Jude Children's Research Hospital
Schering-Plough

Active, not recruiting

Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma

Malignant Melanoma

United States
Novartis Pharmaceuticals

Completed

Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD). (COMBI-AD)

Melanoma

United States, Belgium, Canada, Spain, United Kingdom, Netherlands, Argentina, Australia, Austria, Brazil, Czechia, Denmark, France, Germany, Greece, Israel, Italy, Japan, New Zealand, Norway, Poland, Russian Federation, Sweden, Switz... and more
Merck Sharp & Dohme LLC
European Organisation for Research and Treatment of Cancer

Active, not recruiting

Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054)

Melanoma
Melanoma and Skin Cancer Trials Limited
Monash University; University of Sydney; The University of Queensland

Active, not recruiting

Melanoma Surveillance Photography (MSP) to Improve Early Detection of Melanoma in Ultra-high and High Risk Patients (IMAGE)

Melanoma | Skin Cancer | Anxiety and Fear

Australia
Nektar Therapeutics
Bristol-Myers Squibb

Terminated

Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12)

Melanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III

United States, Spain, Germany, France, Australia, Italy, Greece, Israel, Russian Federation, New Zealand, Austria, United Kingdom, Netherlands, Portugal, Poland, Czechia, Romania
Suthee Rapisuwon
Bristol-Myers Squibb

Active, not recruiting

Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma

Melanoma | Ocular Melanoma

United States
Nektar Therapeutics

Terminated

Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors (PROPEL)

Non-Small Cell Lung Cancer

United States, Germany, Spain, Australia, France
Ludwig Institute for Cancer Research
Institute of Cancer Research, United Kingdom

Completed

Study of NY-ESO-1 ISCOMATRIX® in Patients With High-risk, Resected Melanoma

Melanoma

United Kingdom, Australia, New Zealand
Nina Bhardwaj
Memorial Sloan Kettering Cancer Center; NYU Langone Health; Ludwig Institute... and other collaborators

Completed

A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence

Melanoma

United States

Search clinical trials for: high risk melanoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ghana

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations